Daré Bioscience (NASDAQ:DARE) Stock Price Crosses Below 200 Day Moving Average of $0.72

Shares of Daré Bioscience, Inc. (NASDAQ:DARE) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.72 and traded as low as $0.32. Daré Bioscience shares last traded at $0.34, with a volume of 290,033 shares trading hands.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their price objective on Daré Bioscience from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, November 10th.

Daré Bioscience Trading Up 2.4 %

The firm has a market capitalization of $33.81 million, a PE ratio of -0.73 and a beta of 1.26. The business’s 50 day simple moving average is $0.44 and its two-hundred day simple moving average is $0.72.

Institutional Investors Weigh In On Daré Bioscience

A number of hedge funds have recently added to or reduced their stakes in DARE. Bank of New York Mellon Corp purchased a new stake in Daré Bioscience during the 1st quarter valued at $34,000. Citigroup Inc. purchased a new stake in shares of Daré Bioscience in the 1st quarter worth $40,000. BlackRock Inc. increased its stake in shares of Daré Bioscience by 63.7% in the 1st quarter. BlackRock Inc. now owns 602,036 shares of the biotechnology company’s stock worth $897,000 after purchasing an additional 234,243 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Daré Bioscience by 13.0% in the 1st quarter. Vanguard Group Inc. now owns 3,453,021 shares of the biotechnology company’s stock worth $5,145,000 after purchasing an additional 396,968 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Daré Bioscience in the 1st quarter worth $150,000. 7.41% of the stock is currently owned by hedge funds and other institutional investors.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.